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Abstract
Preeclampsia is a common disorder of pregnancy characterized by endothelial dysfunction.
It may be life-threatening for the mother and fetus in severe cases. Dysregulation of the com-
plement system has been suggested to predispose women to preeclampsia. Complement is
part of the innate and adaptive immune systems and potentially capable of causing inflam-
mation and tissue damage. Membrane cofactor protein MCP (CD46) is among the potent
complement regulators that have recently been linked to a severe form of preeclampsia with
or without an underlying autoimmune phenotype. Mutations inCD46 predispose to throm-
botic microangiopathy with endothelial cell dysfunction. The exome of CD46were se-
quenced in 95 Finnish women with severe preeclampsia. Genetic variations discovered in
the full exome were compared to those observed in 95 control women who did not develop
preeclampsia. Because A304V (rs35366573) was associated with preeclampsia in one pre-
vious study, we sequenced the transmembrane region including the A304V variant and part
of the cytoplasmic tail in 95 additional controls. We did not discover any association between
A304V or otherCD46 SNPs and preeclampsia. This study describes a carefully character-
ized cohort of severely preeclamptic Finnish women and found no potentially predisposing
variants inCD46. However, it is possible that other genetic components of the complement
systemmay affect the pathogenesis of severe preeclampsia and related diseases.
Introduction
Preeclampsia is a common (3–5%) disorder of pregnancy. It increases perinatal mortality
five-fold [1]. The onset and clinical course of preeclampsia is unpredictable. It often ne-
cessitates preterm delivery, which carries the risk for complications of prematurity.
PLOSONE | DOI:10.1371/journal.pone.0117840 February 24, 2015 1 / 10
a11111
OPEN ACCESS
Citation: Lokki AI, Aalto-Viljakainen T, Meri S,
Laivuori H, (2015) Genetic Analysis of Membrane
Cofactor Protein (CD46) of the Complement System
in Women with and without Preeclamptic
Pregnancies. PLoS ONE 10(2): e0117840.
doi:10.1371/journal.pone.0117840
Academic Editor: Anne Croy, Queen’s University,
CANADA
Received: September 26, 2014
Accepted: January 1, 2015
Published: February 24, 2015
Copyright: © 2015 Lokki et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Data are available from
the University of Helsinki, Haartman Institute for
researchers who meet the criteria for access to
confidential data. The data of this study may be
requested from Assoc. Prof. Hannele Laivuori
(hannele.laivuori@helsinki.fi).
Funding: The FINNPEC study was supported by
Jane and Aatos Erkko Foundation, Päivikki and
Sakari Sohlberg Foundation, Academy of Finland,
Research Funds of the University of Helsinki, Special
state subsidy for Health Sciences (EVO funding) at
Helsinki and Uusimaa Hospital District, the National
Preeclampsia is also associated with an increased risk of cardiovascular disease in later life
of both the mother and the fetus [2,3]. Although the disease originates early in pregnancy,
the defining symptoms, newly-onset hypertension and proteinuria, develop in the latter
half of pregnancy. Currently, no reliable predictive test for preeclampsia is known and no
cure other than delivery is available.
The complement system is an integral part of the innate immune system consisting of
phylogenetically ancient processes of pathogen recognition and self-/non-self-
discrimination. In a normal pregnancy the complement system becomes activated at a low
level [4]. Activation of the terminal complement pathway leads to formation of the mem-
brane attack complex (MAC) and possible destruction of the target cell. Complement can
be activated via three independent pathways. The lectin pathway (LP) is activated by man-
nose-binding lectin (MBL) and by ficolins. It has previously been studied in association
with preeclampsia with contradictory results [4,5]. The classical pathway (CP) is activated
by the C-reactive protein (CRP) or by immune complexes, such as antibodies bound to
microbes or autoantibodies bound to self-antigens. The role of a microbial trigger for in-
flammation during pregnancy as a causative agent in preeclampsia has been the subject of
a lengthy debate, where no definitive conclusions have yet been achieved [6–9]. An impor-
tant role for the alternative pathway (AP) of complement in abnormal pregnancy was sug-
gested by animal studies over a decade ago, when Crry, the functional murine homologue
of human complement inhibitors membrane cofactor protein (MCP) and decay accelerat-
ing factor (DAF), was knocked out causing infertility due to alternative pathway activation
[10]. Recently, it was shown that an elevated level of alternative pathway activation occurs
also in human pregnancies, where severe preeclampsia develops [11]. Activation of the
complement system must be rigorously regulated in order for normal placentation to
occur and for the placenta to be protected from tissue destruction, thrombosis and antian-
giogenic factors [12,13]. MCP is a widely expressed complement regulator that inhibits
AP, LP and CP. It binds to both C3b (AP) and C4b (CP) and acts as a cofactor for their in-
activation by the C3b/C4b inactivator enzyme factor I [14,15]. MCP is a type 1 membrane
bound protein consisting of an intracellular tail region with several variant structures [7]
a single transmembrane α-helical region, a short region of unknown function (U), a collar
STP- rich region with several variant structures, and finally four extracellular Comple-
ment Control Protein (CCP) domains carrying the cofactor activity (Fig. 1) [15,16].
MCP is encoded by CD46 located in the Regulators of Complement Activation gene
cluster on chromosome 1q32.2. Apart from its role as a complement inhibitor on cell
membranes MCP can act as a receptor for certain pathogens such as the measles virus
(Edmonston strain) [17], human herpesvirus 6 [18] and Neisseria gonorrhoeae [19]. MCP
has also been suggested to have role in the fertilization of the human egg [20]. Notably,
several mutations both in the CCPs as well as in the transmembrane region are linked to
atypical hemolytic uremic syndrome (aHUS) [21,22].While we initiated our studies on the
AP regulatory genes in preeclampsia, MCP among other complement regulators received
considerable attention as potential target for mutations in preeclampsia [12].
We hypothesized that variation in complement regulation might be one underlying reason
for severe preeclampsia in patients who developed heavy proteinuria. The objective of this
study was to investigate whether sequence variations in the CD46 promoter, splice sites and
exome are present in Finnish women with and without preeclampsia. Because A304V
(rs35366573) was associated with preeclampsia in one previous study [12], we studied this
variant in a larger group of controls.
MCP in Preeclamptic Pregnancies
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Methods
STUDY POPULATION
The participants are a subgroup of the FINNPEC (The Finnish Genetics of Preeclampsia Con-
sortium) study cohort. Briefly, at the time of publication, the cohort comprises 1090 women di-
agnosed with preeclampsia in their singleton pregnancy and 930 women without preeclampsia
symptoms in their singleton pregnancy (the control group). Preeclampsia was defined as hy-
pertension and proteinuria occurring after 20 week of gestation. Hypertension was defined as a
systolic blood pressure 140 mmHg, and/or a diastolic blood pressure 90 mmHg. Protein-
uria was defined as the urinary excretion of0.3 g protein in a 24-hour specimen, or 0.3g/L, or
1+ reading on dipstick in a random urine determination at least twice with no evidence of a
urinary tract infection. Intrauterine growth restriction (IUGR) was defined as birth weight
below-2 SD according to the Finnish standards [23].
For this study we selected a subset of 95 primiparous women with severe preeclampsia (a
systolic blood pressure160 mmHg or a diastolic blood pressure110 mmHg or proteinuria
5 g protein in a 24-hour specimen). Because the prominent mutations of CD46 are known to
associate with disorders involving kidney function, we included preeclamptic women with
heavy proteinuria in this study. They had no autoimmune diseases. Twenty-six patients (27%)
Fig 1. The schematic structure of the membrane cofactor protein (CD46). The positions of the amino
acid changing single nucleotide polymorphisms described in Salmon et al. [12] and in this study are depicted.
Inspired by Fang et al. [22].
doi:10.1371/journal.pone.0117840.g001
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had early-onset preeclampsia (diagnosis before 34 weeks of gestation). A control group com-
prised 190 women randomly selected from the original control group. None of the controls
had autoimmune diseases. The clinical characteristics of the two groups are shown in Table 1.
ETHICS STATEMENT
All subjects provided a written informed consent and the FINNPEC study protocol was ap-
proved by the coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa
(permit number 149/E0/07).
LABORATORYMETHODS
DNA was extracted from 10 ml EDTA whole blood stored at-20C° (after initial freezing period
at-80C° to prevent formation of icicles and molecular degradation) using Chemagic Magnetic
Separation Module I (Chemagen, PerkinElmer, Baesweiler, Germany) automatic DNA extrac-
tion protocol as provided by the manufacturer. Extracted DNA was used at final concentra-
tions of 20 ng /μl and 30 ng /μl.
Exomic sequencing inclusive of flanking intronic regions was carried out using 15 pairs of
primers as listed in S1 Table. Promoter region 240 bp upstream of exon 1 was also sequenced.
Primers were designed and tested by using Primer3 and GenomeTester softwares [24,25]. PCR
was carried out using Mytaq (Bioline, London, UK) polymerase enzyme and buffer following
the manufacturer’s protocol. PCR products were purified using ExoSAP-IT (GE Healthcare Life
Science, UK) shrimp phosphatase alkaline product and the purified DNA fragments were se-
quenced by Big Dye Terminator v3.1 Cycle enzyme and buffer (Applied Biosystems, Carlsbad,
CA, USA) following the manufacturer’s protocol. The sequencing reaction product was purified
by Performa DTR v3 filterplates (Edge BioSystems, Gaithersburg, MD, USA) and analyzed
using ABI3730xl capillary electrophoresis sequencer (Applied Biosystems, Carlsbad, CA, USA).
The raw data was analyzed using Sequencher 8 software (Applied Biosystems, Carlsbad, CA,
USA) and the detected polymorphisms were verified using SNPper [26] and NCBI databases.
STATISTICAL METHODS
CD46 sequencing results were analyzed for disease association in PLINK [27]. Association by
individual SNPs and association in terms of different genotypic models were evaluated by Fish-
er’s Exact test. The functionality of amino acid changing SNPs was evaluated using PolyPhen-2
[28] and SIFT [29]. In SIFT, scores< 0.05 or sometimes< 0.1 are considered indication of a
deleterious mutation [30]. An independent values t-test was used to compare means of clinical
characteristics between patients and controls in IBM SPSS statistics version 22 (IBM corp.).
Results
A total of 15 SNPs (Table 2), including three novel ones (Table 3), were observed in CD46. The al-
leles and minor allele frequencies (MAF) in patients and controls are presented in Table 2. Hetero-
zygosity for the A304V variant (rs35366573) was observed in 12% (11/95) of cases and 11% (21/
188) of controls (OR = 0.943, 95% CI = 0.450, 1.978). In addition, one control was homozygous for
A304V. A304V was predicted to be benign (Polyphen2 score 0.011/1) and tolerated (Sift: 0.19).
The K32N variant (rs150429980), an amino acid change in the functional part of the MCPmole-
cule, in the most membrane distal CCP, was observed in a heterozygous form in one patient and in
one control (OR = 1, 95% CI = 0.062, 16.11, S2 Table). K32N was ambivalently predicted to be
probably damaging (Polyphen2 score 0.996/1, sensitivity 0.55, specificity 0.98) or possibly tolerated
MCP in Preeclamptic Pregnancies
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Table 1. Clinical characteristics of the study population.
Severe preeclampsia n = 95 Controls n = 190 Difference between patients
and controlsMean (SD) N (%) Mean (SD) N (%)
Age (years) 29.0 (4.55) 30.8 (4.87) p = 0.003†
Body mass index (kg) 24.2 (4.92) 23.9 (3.72) NS†
Primipara 95 (100%) 104 (55%) p < 0.001‡
Early-onset preeclampsia (diagnoses <34 weeks of gestation) 26 (27%) 0 p < 0.001‡
Systolic blood pressure (mmHg) 173 (15.36) 125 (12.94) p < 0.001†
Diastolic blood pressure (mmHg) 112 (6.92) 83 (7.99) p < 0.001†
Proteinuria (g, 24-hour specimen) 5.8 (4.49) *
Gestational diabetes 2 (2%) 10 (5%) p = 0.005‡
Pre-gestational diabetes (type 1 diabetes) 0 3 (2%) NS‡
Pre-gestational hypertension 1 (1%) 3 (2%) NS‡
Gestational hypertension 0 7 (4%) p = 0.043‡
Weeks of gestation at delivery 36.2 (2.89) 39.9 (1.58) p < 0.001§†
Preterm birth (delivery before 37 weeks of gestation) 39 (42%) 6 (3.2%) p < 0.001‡
Birthweight (g) 2582 (733.86) 3622 (474.27) p < 0.001§†
Intrauterine growth restriction (<-2 SD) 18 (19%) 1 (<1%) p < 0.001‡
The 95 subgrou of controls did not differ statistically from the 190 control pool. The signiﬁcance level is 0.05.
NS—not signiﬁcant
§ Equal variances not assumed
* One individual (0.5%) in the control group had gestational proteinuria.
† T-test
‡ Mann-Whitney U test
doi:10.1371/journal.pone.0117840.t001
Table 2. The observed single nucleotide polymorphisms (SNPs) and minor allele frequencies (MAF) in the genotyped cases and controls.
CHR SNP MAF cases MAF controls N cases N controls Location
1 rs2796268 0.453 0.457 95 94 promoter
1 rs41266397 0.069 0.074 95 95 promoter
1 rs150429980 0.005 0.005 95 94 exon 2 K32N
1 rs12126088 0.011 0.000 95 94 exon 4 synonymous
1 rs41258244 0.069 0.074 95 94 exon 5 synonymous
1 rs2724374 0.247 0.200 95 95 intronic
1 rs35366573 0.058 0.061 95 188 exon 11 A304V
1 NewSNP1 0.000 0.005 92 97 intronic
1 NewSNP2 0.005 0.000 95 94 cytoplasmic tail
1 NewSNP3 0.005 0.000 95 187 cytoplasmic tail
1 rs7144 0.452 0.457 95 94 cytoplasmic tail
1 rs193023975 0.005 0.000 95 94 cytoplasmic tail
1 rs185457983 0.000 0.005 95 94 cytoplasmic tail
1 rs14374 0.053 0.021 95 95 cytoplasmic tail
1 rs1237 0.069 0.042 95 95 cytoplasmic tail
doi:10.1371/journal.pone.0117840.t002
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(Sift: 0.13). One new SNP was located near exon 13, being observed in one control. Two of the new
SNPs were located in exon 14. Both were observed once in a different patient (Fig. 2, Table 3).
Discussion
In this study we did not find any sequence variants in promoters, exomes and flanking regions
of CD46 associated with preeclampsia. Preeclampsia is known to be a clinically variable and eti-
ologically heterogeneous disease [31]. Preeclamptic patients with heavy proteinuria were select-
ed for the project, because several previous studies pointed towards functional problems of the
kidney in association with complement activation and particularly with CD46mutations, as
observed in aHUS [17,21,22,32]. The similar nephrological symptoms between aHUS and pre-
eclampsia led us to pursue a common cause to these two conditions.
Interestingly, Salmon and co-workers reported CD46mutations as genetic defects associated
with preeclampsia [12]. In the PROMISSE cohort consisting of 250 pregnant patients with system-
ic lupus erythematosus (SLE) and/or antiphospholipid antibody (APL Ab) syndrome they found
an increase from 2.5% to 7% in A304V heterozygosity in women, who developed preeclampsia.
They replicated their finding in 59 women with preeclampsia and/or theHELLP (hemolysis, ele-
vated liver enzymes, low platelet count) syndrome and 143 controls without autoimmune diasease
[12]. In the 59 patients, Salmon et al. observed a higher MAF (minor allele frequency 3.4%) than
what was seen in ethnically and geographically matched controls (1.4%, including 1 homozygous
individual) [12]. Our results with a larger study population do not support the previously reported
findings. In the present study, A304V variant was equally prevalent in the two groups. Further-
more, we discovered an individual homozygous for A304V among the healthy controls. MAF for
A304V was 5.4% in 3316 Finnish individuals of the SISu (Sequencing initiative Suomi) data re-
source (www.sisuproject.fi). While NCBI reports heterozygosity in different populations to range
between 2–4%, with MAF of 0.6–2.2%, the highest values being recorded in European popula-
tions, our result together with the SISu data suggests, that an even higher MAF is typical of the
general Finnish population. In light of this evidence it seems unlikely that the increase in MAF
from 2.1% (general population) or 1.4% (healthy geo-ethnically matched pregnant controls) to
3.7% (PROMISSE with preeclampsia) or 3.4% (Utah Severe preeclampsia/HELLP cohort) alone
would bear functional consequences for the development or progression of preeclampsia, as previ-
ously suggested [12]. Furthermore, preeclampsia being a heterogenous disease, different subtypes
such as HELLPmay not be compatible in etiological comparison. Our data set had no patients
with severe immunological diagnoses such as SLE. The patients with severe preeclampsia from
the study by Salmon et al. are comparable to our data set [12].
A304V variant is located in the transmembrane region of the molecule (Fig. 1). The possible
functional role is thus not directly related to interaction with C3b and C4b, which are known
to bind to extracellular CCP regions. The mechanism of decreased alternative pathway regula-
tion associated with A304V is thus not clear [22,33]. We did not find indication of disease
Table 3. Details of the new single nucleotide polymorphisms (SNPs).
SNP ID Allele 1 Allele 2 Genomic position*
NewSNP1 G A 207963561
NewSNP2 G C 207967178
NewSNP3 A G 207967697
* according to build GRCh37.p10
doi:10.1371/journal.pone.0117840.t003
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relatedness of A304V in our bioinformatics analyses in a majority of the transcripts, i.e. splice
variants included in the software analyses.
Salmon et al. found K32N in a patient affected by SLE with a history of repeated pregnancy loss,
fetal death and preeclampsia. This amino acid substitution from basic lysine to neutral asparagine
causes a 4x decrease in the C4b cleavage promoting activity of MCP [12]. In our material K32N
was observed in a heterozygous form in one preeclamptic patient and one control. SISu reports the
MAF of K32N to be 0.03% in 3325 Finnish individuals. In the bioinformatics analyses the possible
functional effects of K32N were controversial. While SIFT predicted K32N to be tolerated, Poly-
phen2 predicted it to have deleterious changes for the protein function in all available transcripts.
Preeclampsia being a clinically variable and heterogeneous disease, it is always a challenge to
pinpoint an association to link single gene variant to a particular subphenotype. The missing as-
sociation between CD46mutations and preeclampsia may also be attributed to incomplete pene-
trance of complement mutations in preeclampsia. Furthermore, the multifactorial background is
another likely explanation for missing association in a complex disease like preeclampsia. The
present study does not account for the effect of disease specific isoforms in preeclampsia. While
several splicing isoforms of CD46 have been known to exist for a long time recent work suggests
a disease specific role for the occurrence of CD46 isoforms [7]. Exons 13 and 14 code for the
large cytoplasmic tail section of the molecule, which is variably included or spliced out from the
functional isoforms of the protein (Fig. 1) [21]. The functional effects of the new SNPs discovered
in these exons fundamentally depend on whether they are included in the isoform in question.
As discussed above, the complement system has an essential role in pregnancy. The overrid-
ing hypothesis is that excessive and uncontrolled activation of the maternal complement sys-
tem compromises the placenta and ultimately the fetus [12,13]. Accordingly, it is not likely that
malfunctioning maternal MCP, being a cell-bound regulator of the complement system, would
have a fundamental effect on the integrity of tissues of fetal origin such as the placenta. Mater-
nal activators and fetal regulators are the more obvious molecules of interest in future studies.
In this study we have explored the genetic polymorphism of CD46 in preeclampsia. Three
novel rare variants were discovered but neither they nor other polymorphisms of interest were
associated with severe preeclampsia. Studies on functional CD46 isoforms in preeclampsia may
provide further insight into the possible role of MCP and complement-mediated injury in the
pathogenesis of severe preeclampsia.
Fig 2. The sequences of the newly discovered SNPs near exon 13 and in exon 14 of theCD46. Panel A: New SNP1 G/A heterozygote (top) and A/A
homozygote (bottom). Panel B: New SNP2 G/C heterozygote (top) and C/C homozygote (bottom). Panel C: New SNP3 A/G heterozygote (top) and G/G
homozygote (bottom).
doi:10.1371/journal.pone.0117840.g002
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